VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington’s disease
Citations Over TimeTop 10% of 2016 papers
Abstract
Mutant Huntingtin (mtHtt) causes neurodegeneration in Huntington's disease (HD) by evoking defects in the mitochondria, but the underlying mechanisms remains elusive. Our proteomic analysis identifies valosin-containing protein (VCP) as an mtHtt-binding protein on the mitochondria. Here we show that VCP is selectively translocated to the mitochondria, where it is bound to mtHtt in various HD models. Mitochondria-accumulated VCP elicits excessive mitophagy, causing neuronal cell death. Blocking mtHtt/VCP mitochondrial interaction with a peptide, HV-3, abolishes VCP translocation to the mitochondria, corrects excessive mitophagy and reduces cell death in HD mouse- and patient-derived cells and HD transgenic mouse brains. Treatment with HV-3 reduces behavioural and neuropathological phenotypes of HD in both fragment- and full-length mtHtt transgenic mice. Our findings demonstrate a causal role of mtHtt-induced VCP mitochondrial accumulation in HD pathogenesis and suggest that the peptide HV-3 might be a useful tool for developing new therapeutics to treat HD.
Related Papers
- → Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease(2007)112 cited
- → Impaired mitochondrial trafficking in Huntington's disease(2009)67 cited
- → The calpain-suppressing effects of olesoxime in Huntington's disease(2016)15 cited
- → Recent Trends in Detection of Huntingtin and Preclinical Models of Huntington’s Disease(2014)5 cited
- Assessments of potential interactions of huntingtin-associated-protein-1 in the R6/2 mouse model of Huntington's disease(2004)